We believe great partnerships create great possibilities and are inspired by our partners
As a global biopharmaceutical company, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
Exclusively sourcing our pipeline through external innovation, we have no internal competing pipeline as we recognize the best science is delivered in biotech and academic institutions. We are proud our team comprises talents attracted from Pharma, biotech and academia, to drive shared success through creative collaborations.
We have the tenacity
to carry your innovations forward
Ipsen Key Facts
Impact across the globe
Represented in 88 countries, our commercial sales have strong coverage across North America (33%), Europe (40%), and the rest of world (27%) with our medicines showing best-in-class commercial performance.
Our North America base has grown rapidly: 600% over the last 6 years reaching >$1bn in 2022.
Strength in numbers: a strong pipeline
Since 2020, Ipsen has brought in over 20 best- or first-in-class programs across our pipeline at every stage of development and plans are in place to acquire more.
We are focused. We invest in opportunities in challenging disease areas to better address challenges faced by the community.
Acquiring Epizyme & Tazverik®
Ipsen acquired Epizyme in 2022, and with it Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor, strengthening our oncology pipeline and reinforcing our focus on solid tumors and hematological malignancies.
Integrating Albireo & Bylvay®
In 2023, Ipsen acquired Albireo, accelerating our growth in rare disease with treatments for pediatric liver diseases. With Bylvay® (odevixibat), we boost our expertise in treating pruritus in young people with progressive familial intrahepatic cholestasis (PFIC). With Bylvay® (odevixibat) we boost our expertise in rare liver diseases in progressive familial intrahepatic cholestasis (PFIC) and Alagille Syndrome. The Phase III BOLD study in Biliary Atresia remains ongoing. This partnership also results in a number of other assets joining our clinical pipeline.
Recognition on the global stage
Ipsen was named SCRIP’s 2023 BD Team of the Year and 2022 Pharma BD Team of the year at the European Lifestars Award.
Focused and fast
Guided by our strategy, we move fast to make deals with like-minded partners. That’s how we were able to make two acquisitions in less than nine months.
Contact the partnering team
At Ipsen, entering partnerships is always personal. Our team is committed to success and has the expertise to deliver it. Contact us to see how together, we can accelerate innovation for patients.
Partnering events
Throughout the year, Ipsen holds numerous events for and with partners. Look through our upcoming events if you are interested in our work and in partnering with us and would like to meet our team.
